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BETWEEN April 1978 and December 1979, 83 
recipients of cadaveric renal homografts were 
submitted to prolonged thoracic duct drainage as 
part of the immunosuppressive treatment. Our 
motivation for the thoracic duct drainage trial 
was dissatisfaction with the so-called standard 
immunosuppressive regimens for cadaveric kid-
ney transplantation (24). 
From this experience (11, 20, 22, 23), it 
became possible to suggest that the main value of 
thoracic duct drainage was for pretreatment, to 
define the appropriate time of the conditioning 
period before transplantation and to relate the 
need for thoracic duct drainage to the pre-existing 
or developing antibody status of the patient. The 
clinical results with optimally applied thoracic 
duct drainage were improved over our past ex-
perience in cadaveric transplantation. However, 
the follow-up periods were so short (11, 22, 23) 
that a catch-up graft loss or a delayed patient 
mortality were still possibilities. Now, all of the 
surviving recipients to be reported upon have 
been observed for at least one year. 
METHODS 
Cervical thoracic duct drainage was estab-
lished as described before (12, 20, 22, 23). The 
general conditions of the trial have been described 
earlier (22, 23). Because the cadaveric kidneys 
were from randomly matched donors, the an-
tigens, when analyzed of the HLA-A, B and DR 
loci, were always poorly matched. There were 
only two instances in which there were fewer 
than two mismatches at the A and B loci and none 
in which there was a four antigen match. 
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Except when stipulated otherwise, the patients 
with thoracic duct drainage were given grafts 
from donors against whose tissues the recipient 
sera did not have warm anti-T lymphocyte an-
tibodies. The presence or absence of recipient an-
tibodies of several types influenced the duration of 
thoracic duct drainage in much of our later expe-
rience (22, 23) in that patients with preformed 
warm antibodies tended to be pretreated longer. 
In analyzing the results of graft survival, atten-
tion was paid only to the kidney which was trans-
planted at the time the patient was entered into a 
given study series. Thus, a successful retrans-
plantation which was common in some of the 
groups (22) would not be reflected in the data as 
presented. No patients were excluded except a 
recipient of a pancreas plus a kidney who died of 
sepsis more than two months later. 
The patients were 11 to 60 years old. As de-
scribed earlier (22, 23), recipients were not ex-
cluded because of high risk factors, including age, 
vascular disease and myocardial dysfunction. Ten 
patients had diabetes mellitus. 
Azathioprine and prednisone were begun on 
the day of the transplantation. The daily azathio-
prine dosage was designed to avoid leukopenia. 
The prednisone dose was 200 milligrams on the 
first day. Thereafter, daily reductions by 10 milli-
grams were made, if rejection did not supervene, 
until a daily dose of 40 milligrams was reached in 
16 days. Further reductions were individualized, 
usually with monthly decrements of 5 milligrams. 
Thirty-five recipients were also given short 
courses of an antithymocyte globulin that was 
thought not to be an influential factor (22). 
Slightly less than one-half of the patients under-
went splenectomy. This incidence of splenectomy 
was about the same in the patients treated with 
thoracic duct drainage as in those in the retro-
spective control group. Splenectomy was usually 
performed because of relative leukopenia. 
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TABLE I-GRAFT LOSSES AFTER PRIMARY CADAVERIC TRANSPLANTION AT THREE AND 12 MONTHS 
POSTOPERATIVE 
Control, n=51 .......................... . 
Contemporaneous TTD, n=25 ............. . 
Pretreatment TDD, Total n=40 ............ . 
<28 days, n=18 ...................... . 
~OU days, n=22 ..................... . 
• Including death. 
TDD, Thoracic duct drainage. 








1 ( 4.5.) 
In the first patients, thoracic duct drainage was 
begun at the time of transplantation and contin-
ued for 20 to 109 days. In later patients, pretreat-
ment with thoracic duct drainage was always 
used and for periods of 17 to 58 days. After trans-
plantation, thoracic duct drainage was usually 
continued for three or four weeks. It was 
documented earlier that effective pretreatment 
with thoracic duct drainage for a period of four 
weeks or longer virtually eliminated rejection 
during the first two months after transplantation 
(23) . 
Rejection was defined as a secondary rise of 
creatinine of more than 25 per cent above base 
line, along with the other biochemical findings of 
renal failure. The characteristic physical signs of 
rejection were looked for as well as the typical 
findings of rejection by radionuclide scanning. 
The case material was divided for analysis into 
group 1, 25 consecutive reci pients of first cadaver-
ic kidneys had thoracic duct drainage at the same 
time as transplantation; and group 2, 40 consecu-
tive recipients of first cadaveric kidneys had tho-
racic duct drainage for two and a half weeks to 
one and a half months before transplantation and 
for variable periods afterwards. 
Retrospective controls for both groups 1 and 2 
were provided by 51 consecutive recipients of first 
cadaveric grafts who had undergone transplanta-
tions from May 1977 to l\..farch 1978. 
Group 3 consisted of 12 patients who had 
cadaveric retransplantation after having pre-
viously rejected from one to four kidneys. The 
first five of these recipients had thoracic duct 
drainage begun on the day of transplantation and 
the next seven had thoracic duct drainage pre-
treatment for four weeks to two months. 
Group 4 was made up of six patients who had 
warm anti-T antibodies against all of the lym-
phocytes of a screening panel of 30 healthy volun-
teers (22). The patients were standard cross 
match positive against the donors. Such comli-
tions have been shown by Terasaki and co-
workers (25) to dispose to hyperacute rejection. 
No. of grafts 
lost from rejection 
within 3 months 
20 (39.2) 
8 (32.0) 
3 ( 7.5) 
2 (11.1) 
1 ( 4.5) 
No. of grafts 
lost to rejection 





2 ( 9.1) 
Total no. of grafts 
lost from all causes· 






Pretreatment with thoracic duct drainage was 
carried out for 25 to 54 days (22). 
RESl'L'rS 
Primary Cadaveric Transplantation 
Early rejection. Within the first three months, 
the clinical diagnosis of rejection was made in 35 
of the 51 retrospective control recipients. In 20 
patients, the rejections were irreversible (Table 
I) . The incidence of early rejection was not mark-
edly altered by beginning thoracic duct drainage 
at the time of transplantation, group 1, although 
fewer of the primary homografts were lost (Table 
I) . 
In group 2, when pretreatment with thoracic 
duct drainage was used for less than four weeks, 
the incidence of rejection still was 44.4 per cent, 
but the acute process was seldom irreversible 
(Table I). With pretreatment for four weeks or 
longer, only one rejection occurred during the 
first three months for an incidence of 4.5 per cent 
Cl'able I). 
Kidney survival . . fhere were 30 patients of the 
retrospective control group who still had func-
tioning first grafts at the end of three months. By 
the end of six months, five more organs had been 
lost, and at the end of the year, only 22 remained 
(Fig. 1). By the end of 12 months, these results 
were almost exactly the same as the national 
average reported in the multicenter compilation 
of Opelz and associates (17). 
The one year results in the 25 patients in group 
1 who had contemporaneous thoracic duct drain-
age were slightly better. By the end of the year, 14 
of the original grafts were still functioning. How-
ever, during the ensuing few months, four more 
kidneys were lost. Thus, the actual 18 month 
graft survival rate was 40 per cent, slightly lower 
than that for the retrospective control patients 
(Fig. 1). 
The patients in group 2 who had pretreatment 
with thoracic duct drainage for less than 28 days 
also had an improved one year survival time (Fig. 
1) . Twelve of the 18 still had, and still have, via-
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FIG. 1. Actual graft survival in primary cadaveric renal transplant. Thoracic duct drainage, 7 DD. 
ble grafts. However, two of these recipients who 
are now 17 and 18 months postoperative have 
serum creatinine levels of 4 to 6 milligrams per 
cent. They are expected to lose the grafts, and if 
they do, the graft survival rate will fall to 50 per 
cent. 
Sixteen of the 22 patients in group 2 who had 
pretreatment with thoracic duct drainage for 28 
days or longer had one year graft survival (Fig. 
1) . This early improvement in results was eroded 
by the loss of a kidney each in the 13th and 16th 
months, for a current 12 to 18 month follow-up 
organ survival rate of 63.6 per cent, 14 in 22. If 
an additional kidney is rejected by a patient with 
a serum creatinine level that is now 5 milligrams 
per cent in the 17th postoperative month, the kid-
ney survival rate will drop to 59.1 per cent. 
Patient sumiuaf. In the study groups shown in 
Figure 1, the mortality during the first postopera-
tive year ranged from 12 to 22.7 per cent (Fig. 
2) . The lowest early death rate was in those pa-
tients having contemporaneous thoracic duct 
drainage, but two additional deaths that occurred 
shortly after the end of the first year eliminated 
this advantage. 
The most common reason for death was infec-
tion, myocardial infarction being about a fourth 
as frequent a cause. In the group receiving tho-
racic duct drainage pretreatment for more than 
28 days, five patients died within one year. Three 
of the deaths were unrelated to immunosuppres-
sion therapy. There were two myocardial infarc-
tions and one pulmonary emboli. One patient 
with diabetes died of septicemia at 11 months 
after undergoing a hip replacement. 
CADA VERIC RETRANSPLANT A TION 
The five patients in group 3 who had begun 
thoracic duct drainage on the day they were given 
second to fifth kidneys had unacceptable results 
previously shown by Ascher and colleagues (2) 
and by us (8) to be characteristic of cadaveric re-
transplantation. Four of the five grafts were lost 
after three to nine months, and in the process, two 
of these patients died. The fifth patient died of in-
fection just after one year with a well functioning 
kidney. 
The seven patients who had pretreatment with 
thoracic duct drainage for 28 to 58 days fared 
slightly better. One patient suffered an irrevers-
ible rejection after one month. Two patients died 
of infection after four and seven months with well 
functioning kidneys. Three others are in excellent 
health from 13 to 21 months postoperative. The 
seventh patient had slow rejection of his kidney 
after a year and has been returned to dialysis 
therapy. 
TRANSPLANTATION TO PRESENSITIZED RECIPIENT 
As reported before (20, 22), tbree of the six 
patients with broadly reacting warm anti-T 
lymphocyte antibodies escaped hyperacute rejec-
tion. Unfortunately, their painfully won kidneys 
were slowly rejected after eight, 11 and 13 
months. One of the latter patients died of infec-
tion. The five other patients are back on dialysis. 
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FIG. 2. Actual patient survival in primary cadaveric transplant. Thoracic duct drainage, TDD. 
DISCUSSION 
The results of these investigations, as well as 
other recent studies carried out by Johnson and 
colleagues (9), Kaplan (10), Niblack (16), 
Traeger (26) and Walker (27) and their as-
sociates, have supported the value of thoracic duct 
drainage as an immunosuppressive adjunct, thus 
confirming the expectations of earlier workers, 
including those of Archimbaud (1), Fish (5), 
Frankson (6, 7), Murray (14), Newton (15) 
and Sarles (18) and their associates. In earlier 
publications (11, 23), as well as in the present 
report, the conditions were defined whereby max-
imum benefit of thoracic duct drainage could be 
expected. The most important factor was lym-
phoid depletion for at least four weeks prior to 
transplantation. The results using early rejection 
as an immunologic barometer showed the same 
one month time curve of thoracic duct drainage 
effectiveness that had been defined earlier with 
classical immunologic tests by Machleder and 
Paulus (13) in patients with autoimmune disease 
and by us (22, 23) with serologic and other tests 
in transplant recipients. 
The most significant data were obtained in pa-
tients undergoing cadaveric renal transplantation 
for the first time. As reported earlier (23), the 
conclusion was inescapa ble that pretreatment 
with thoracic duct drainage should be provided 
for at least four weeks. When this was done, 
rejection in primary cadaveric graft recipients 
was almost eliminated during the first three 
months and also for significant subsequent times. 
Treatment for 17 to 27 days was demonstrably 
less effective. Finally, whcn thoracic duct drain-
age was begun on the day of transplantation, 
there was little if any tangible benefit for the first 
homograft, although subsequent retransplanta-
tion was seemingly expedited by continuation of 
lymph drainage (20, 22) . 
In all the series, the incidence of renal function 
at one year was increased and with a patient mor-
tality that was not higher than had been observed 
by us with conventional immunosuppression. 
However, the significance of these findings was 
diminished by subsequent graft losses which 
brought the renal survival curves toward, but not 
down to, those attainable by conventional im-
munosuppression. In the patients given optimal 
pretreatment for more than four weeks, the quali-
ty of results was even better than expressed by the 
statistics since grafts were lost late from deaths 
which were not obviously related to the trans-
plantation. 
If there were an enduring influence of the tem-
porary therapeutic maneuver of thoracic duct 
drainage, it would have to be explained by the 
various and not mutually exclusive hypotheses of 
graft acceptance that have been discussed else-
where (19). In such hypotheses, the continuing 
presence of homograft antigen plus nonspecific 
immunosuppression has been envisioned as caus-
ing specific clone depletion and then tolerance, or 
alternativel y, as producing enhancing antibodies. 
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Cicciarelli and co-authors (4) have shown drastic 
changes in the residual thoracic duct cell popula-
tion of patients pretreated only with thoracic duct 
drainage for a month or longer. A large per cent 
of these remaining cells have had features of both 
T cells and B cells. Cicciarelli and associates (4) 
have speculated that the presence of such pre-
sumably pluripotential lymphocytes may signal 
that conditions are propitious for tolerance induc-
tion. 
Our experience with late graft failures has sug-
gested that, if such an advantage is created by 
thoracic duct drainage, it may ultimately be 
diminished. It is probable that the same applies to 
other lymphoid depleting procedures, such as an-
tilymphocyte globulin and lymphapheresis which 
are used temporarily. The lesson has been re-
learned that more effective early therapy is only 
part of the answer which, for full exploitation, 
must be succeeded by improved chronic immuno-
suppression. It is possible that this can be 
achieved with the new immunosuppressive agent, 
cyclosporin A, which was introduced by CaIne 
and colleagues (3) and tested extensively by us 
(21) . 
In spite of evidence that effective and safe 
recipient conditioning can be achieved with tho-
racic duct drainage, the extent to which this 
procedure will be used in the future remains un-
clear. Aside from its personal inconvenience to 
the patients, the necessity for a month or more 
hospitalization period before transplantation has 
engendered substantial hospitalization costs. In 
the United States, funding for thoracic duct 
drainage has been difficult to assure because of 
the unclassified position of this procedure be-
tween patient service and research. It is possible 
that the main use of thoracic duct drainage will be 
in complicated instances in which the patients are 
undergoing retransplantation or possess widely 
reactive anti-T warm antibodies. Thoracic duct 
drainage apparently helped the avoidance of 
hyperacute rejection in one-half of our six pa-
tients (22) with such warm antibodies, but the 
grafts were slowly rejected months later. Al-
though the experience of Niblack and co-workers 
(16) in these difficult instances has been con-
siderably more encouraging, the mere avoidance 
of an early immunologic calamity will not be a 
definitive achievement until the succeeding treat-
ment can be perfected. Here also, cyclosporin A 
may playa role. The combination of thoracic duct 
drainage, cyclosporin A and low dosages of pred-
msone has been shown to be safe and efficient 
(21) . 
SUMMARY 
Thoracic duct drainage was added to conven-
tional immunosuppression with azathioprine, 
prednisone and, sometimes, antilymphoctye glob-
ulin in 83 patients given cadaveric kidneys, in-
cluding 65 primary graft recipients. The most 
effective use of thoracic duct drainage was for 
pretreatment. Optimal conditioning was at least 
four weeks duration, and when lymph drainage 
was this long, the incidence of rejection during the 
first three postoperative months was reduced to 
4.5 per cent. Shorter pretreatment or institution 
of thoracic duct drainage contemporaneous with 
transplantation were less effective, but the one 
year results were still better than those with con-
ventional immunosuppression alone. However, 
the advantage gained with thoracic duct drainage 
during the first year was diminished in all the 
treatment groups by graft losses in the second 
postoperative year. It was concluded that, with-
out better maintenance therapy, the full value of 
temporary early lymphoid depletion procedures 
cannot be fully exploited. 
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